The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
A new study has suggested a new approach to drug design, which
recommends that a loose fit may be the best fit especially when
producing drugs for thyroid related conditions.